Telotristat Ethyl for Reducing Intraoperative Carcinoid Crisis in Patients With Neuroendocrine Tumors

Inclusion Criteria: * Patients must have a grade 1 or grade 2 small bowel, neuroendocrine tumor (NET) that has been medically confirmed by a physician. * Patients who plan to have abdominal (stomach) surgery due to cancer that has spread to their liver. Patients must voluntarily choose to have surgery. * 18 years old or older. * Patients with small bowel neuroendocrine tumors who are asymptomatic (not showing symptoms) but have elevated serotonin or 5-HIAA (5-hydroxyindoleacetic acid) levels before surgery. * Patients who are symptomatic (showing carcinoid symptoms) and have elevated or normal Serotonin or 5-HIAA levels (plasma or urinary) before surgery. Exclusion Criteria: * Patients belonging to vulnerable populations such as children and prisoners. * Patients with grade 3 neuroendocrine tumors or neuroendocrine tumors that are hard to identify. * Patients with untreated carcinoid heart disease. * Patients who are receiving any other drugs or treatment as part of a research study. * Patients with a "currently active" second tumor other than non-melanoma skin cancers. Patients are not considered to have a "currently active" tumor if they have completed therapy and are free of disease for 3 or more years. * Patients with known brain cancers. * Patients who have a history of allergic reactions to medications that have similar chemical or biologic ingredients as those found in telotristat ethyl. * Uncontrolled illness that occurs while having cancer such as, but not limited…